Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Neurologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis.J Affect Disord. 2016; 190: 264-271
- Prevalence of depression, anxiety, and apathy symptoms across dementia stages: A systematic review and meta-analysis.Int J Geriatr Psychiatry. 2021; 36: 1330-1344
- Neuropsychiatric and cognitive symptoms across the Alzheimer disease clinical spectrum: cross-sectional and longitudinal associations.Neurology. 2021; 97: e1276-e1287
- Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria.Int Psychogeriatr. 2018; 30: 185-196
- Agitation and impulsivity in mid and late life as possible risk markers for incident dementia.Alzheimers Dement (N Y). 2020; 6: e12016
- Managing behavioral and psychological symptoms of dementia.Psychiatr Clin North Am. 2018; 41: 127-139
- Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study.Am J Psychiatry. 2015; 172: 460-465
- Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis.Int Psychogeriatr. 2017; 29: 195-208
- Factors influencing hospital admission among patients with autopsy-confirmed dementia.Psychogeriatrics. 2019; 19: 255-263
- Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer’s disease.Int Psychogeriatr. 2018; 30: 1131-1138
- Which factors increase informal care hours and societal costs among caregivers of people with dementia? A systematic review of Resource Utilization in Dementia (RUD).Health Econ Rev. 2021; 11: 37
- Time to invest in prevention and better care of behaviors and psychological symptoms associated with dementia.Int Psychogeriatr. 2020; 31: 1-6
- Instruments to measure behavioural and psychological symptoms of dementia.Int J Methods Psychiatr Res. 2014; 23: 69-98
- The neuropsychiatric inventory: development and applications.J Geriatr Psychiatry Neurol. 2020; 33: 73-84
- The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review.Dement Geriatr Cogn Disord. 2014; 38: 89-146
- Common sense: addressed to geriatric psychiatrists on the subject of behavioral and psychological symptoms of dementia.Am J Geriatr Psychiatry. 2015; 23: 1209-1213
- Ages at onset of anxiety and depressive disorders in parkinson’s disease.J Neuropsychiatry Clin Neurosci. 2019; 31: 346-352
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.Brain. 2011; 134: 2456-2477
- Detroit expert panel on assessment and management of neuropsychiatric symptoms of dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel.J Am Geriatr Soc. 2014; 62: 762-769
- Targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms: A cluster randomized controlled trial.Am J Geriatr Psychiatry. 2018; 26: 25-38
- Predictors of non-pharmacological intervention effect on cognitive function and behavioral and psychological symptoms of older people with dementia.Geriatr Gerontol Int. 2017; 17: 28-35
- Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004-2013.Am J Geriatr Psychiatry. 2015; 23: 1259-1269
- Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: a meta-analysis.Clin Interv Aging. 2008; 3: 719-728
- Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis.J Alzheimers Dis. 2017; 60: 401-425
- Combination therapy showed limited superiority over monotherapy for Alzheimer disease: a meta-analysis of 14 randomized trials.J Am Med Dir Assoc. 2016; 17: 863.e1-863.e8
- Depressive symptoms imputed across the life course are associated with cognitive impairment and cognitive decline.J Alzheimers Dis. 2021; 83: 1379-1389
- Late-life depression and increased risk of dementia: a longitudinal cohort study.Transl Psychiatry. 2021; 11: 147
- Risk of incident dementia varies with different onset and courses of depression.J Affect Disord. 2021; 282: 915-920
- The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset?.Neuropathol Appl Neurobiol. 2009; 35: 406-416
- Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer’s disease pathology at death.Int J Geriatr Psychiatry. 2021; 36: 713-721
- Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson’s disease: a cross-sectional study.J Neurol Neurosurg Psychiatr. 2021; 92: 158-164
- Cognitive behavioural therapy can be effective in treating anxiety and depression in persons with dementia: a systematic review.Psychogeriatrics. 2019; 19: 264-275
- Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.Cochrane Database Syst Rev. 2014; : CD009125
- Effects of Mindfulness-based Interventions on Dementia Patients: a meta-analysis.West J Nurs Res. 2020; 42: 1163-1173
- Treatment for depression comorbid with dementia.Evid Based Ment Health. 2019; 22: 167-171
- Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis.BMJ. 2021; 372: n532
- The effects of bright light treatment on affective symptoms in people with dementia: a 24-week cluster randomized controlled trial.BMC Psychiatry. 2021; 21: 377
- Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis.J Alzheimers Dis. 2017; 58: 725-733
- Antidepressants for treating depression in dementia.Cochrane Database Syst Rev. 2018; 8: CD003944
- Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis.Ageing Res Rev. 2021; 69: 101362
- Frontotemporal dementia: a randomised, controlled trial with trazodone.Dement Geriatr Cogn Disord. 2004; 17: 355-359
- Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data.Int J Geriatr Psychiatry. 2021; 25https://doi.org/10.1002/gps.5625
- Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.Am J Geriatr Psychiatry. 2019; 27: 920-931
- A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia.Int J Geriatr Psychiatry. 2000; 15: 295-305
- A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia.Dement Geriatr Cogn Disord. 2007; 24: 36-41
- Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.J Clin Psychiatry. 2003; 64: 875-882
- Treatment effects of vortioxetine on cognitive functions in mild Alzheimer’s disease patients with depressive symptoms: a 12 month, open-label, observational study.J Prev Alzheimers Dis. 2019; 6: 192-197
- Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population.Pharmacol Res Perspect. 2019; 7: e00461
- The relationship between anxiety and alzheimer’s disease.J Alzheimers Dis Rep. 2021; 5: 171-177
- Frequency and characteristics of anxiety among patients with Alzheimer’s disease and related dementias.J Neuropsychiatry Clin Neurosci. 2003; 15: 180-186
- Non-Pharmacological interventions for the anxiety in patients with dementia. A cross-over randomised controlled trial.Behav Brain Res. 2020; 390: 112617
- Music-based therapeutic interventions for people with dementia.Cochrane Database Syst Rev. 2018; 7: CD003477
- Cognitive behavioral therapy for mood and insomnia in persons with dementia: A systematic review.Alzheimer Dis Assoc Disord. 2021; 35: 366-373
- Buspirone for the treatment of dementia with behavioral disturbance.Int Psychogeriatr. 2017; 29: 859-862
- Becoming or remaining agitated: the course of agitation in people with dementia living in care homes. The english longitudinal managing agitation and raising quality of life (MARQUE) study.J Alzheimers Dis. 2020; 76: 467-473
- The individual course of neuropsychiatric symptoms in people with Alzheimer’s and Lewy body dementia: 12-year longitudinal cohort study.Br J Psychiatry. 2020; 216: 43-48
- Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: a systematic review and Bayesian network meta-analysis.Int J Nurs Stud. 2020; 102: 103489
- Comparative efficacy of interventions for aggressive and agitated behaviors in dementia: a systematic review and network meta-analysis.Ann Intern Med. 2019; 171: 633-642
- Time to response to citalopram treatment for agitation in Alzheimer disease.Am J Geriatr Psychiatry. 2015; 23: 1127-1133
- Efficacy and safety of citalopram compared to atypical antipsychotics on agitation in nursing home residents with alzheimer dementia.J Am Med Dir Assoc. 2017; 18: 799-802
- Sedation mediates part of Citalopram’s effect on agitation in Alzheimer’s disease.J Psychiatr Res. 2016; 74: 17-21
- Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.Lancet. 2021; 398: 1487-1497
- A European Academy of Neurology guideline on medical management issues in dementia.Eur J Neurol. 2020; 27: 1805-1820
- Real-world treatment patterns and characteristics among patients with agitation and dementia in the United States: findings from a large, observational, retrospective chart review.J Alzheimers Dis. 2020; 77: 1181-1194
- Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.Br J Clin Pharmacol. 2018; 84: 1445-1456
Schedule of Pharmaceutical Benefits, General Pharmaceutical Schedule - Volume 1, published by: Australian Government, Department of Health. Canberra, Commonwealth of Australia.January 2022. Available at: https://www.pbs.gov.au/publication/schedule/2022/07/2022-07-01-general-%20schedule-volume-1.pdf.
- Opinion following an article 30 referral for risperdal and associated names.European Medicines Agency, London2008
- Risperidone - Restriction of the Dementia Indication - Recalls and safety alerts.(Available at:) (Accessed January 18, 2022)
- Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.Am J Geriatr Psychiatry. 2007; 15: 918-931
- Low dose lithium treatment of behavioral complications in Alzheimer’s disease: lit-AD randomized clinical trial.Am J Geriatr Psychiatry. 2021; https://doi.org/10.1016/j.jagp.2021.04.014
- Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: systematic review.Trends Psychiatry Psychother. 2021; https://doi.org/10.47626/2237-6089-2021-0288
- Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer’s disease psychosis: a post hoc analysis.Int J Geriatr Psychiatry. 2020; 35: 1402-1408https://doi.org/10.1002/gps.5381
- Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial.JAMA. 2015; 314: 1242-1254
- Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis.BMC Geriatr. 2020; 20: 212
- Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.Am J Psychiatry. 1998; 155: 54-61
- Pharmacological treatment trials of agitation in Alzheimer’s disease: a systematic review of ClinicalTrials.gov registered trials.Alzheimers Dement (N Y). 2021; 7: e12157
- The incidence of dementia-related psychosis in people with dementia: Results from a survey of 302 U.S. healthcare providers.Alzheimers Dement. 2020; 16https://doi.org/10.1002/alz.047138
- Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality.Am J Geriatr Psychiatry. 2013; 21: 1135-1143
- Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.JAMA Psychiatry. 2015; 72: 438-445
- Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials.J Clin Psychopharmacol. 2019; 39: 472-478
- The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.Lancet Neurol. 2009; 8: 151-157
- Five things physicians and patients should question.American Psychiatric Association Choosing wisely, Philadelphia, PA2013
- American Geriatrics Society | Choosing Wisely.(Available at:) (Accessed January 3, 2022)
- Evidence-based treatment and monitoring strategies for dementia-related psychosis.J Clin Psychiatry. 2021; 82https://doi.org/10.4088/JCP.AD19038BR4C
- Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia-related psychosis (DRP): a systematic literature review.J Prev Alzheimers Dis. 2021; 8: 520-533
- Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis.JAMA Netw Open. 2019; 2: e190828
- Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia.Cochrane Database Syst Rev. 2021; 12: CD013304
- Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.Lancet Neurol. 2018; 17: 213-222
- Trial of Pimavanserin in Dementia-Related Psychosis.N Engl J Med. 2021; 385: 309-319
- Difficult choices in treating Parkinson’s disease psychosis.Lancet Neurol. 2018; 17: 569
- Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms.Brain. 2021; 144: 999-1012
- Psychosis management in lewy body dementia: A comprehensive clinical approach.J Geriatr Psychiatry Neurol. 2021; 19https://doi.org/10.1177/0891988720988916
- Treatment of psychosis in Parkinson’s disease and dementia with Lewy Bodies: a review.Parkinsonism Relat Disord. 2020; 75: 55-62
- New evidence on the management of Lewy body dementia.Lancet Neurol. 2020; 19: 157-169
- Apathy and disinhibition related to neuropathology in amnestic versus behavioral dementias.Am J Alzheimers Dis Other Demen. 2019; 34: 337-343
- What do we mean by behavioral disinhibition in frontotemporal dementia?.Front Neurol. 2021; 12: 707799
- The hyperactivity-impulsivity-irritiability-disinhibition-aggression-agitation domain in Alzheimer’s disease: current management and future directions.Front Pharmacol. 2019; 10: 1109
- Treatment and management of sexual disinhibition in elderly patients with neurocognitive disorders.Cureus. 2021; 13: e18463
- Criminal behavior in frontotemporal dementia and Alzheimer disease.JAMA Neurol. 2015; 72: 295-300
- Effectiveness of pharmacological interventions for symptoms of behavioral variant frontotemporal dementia: a systematic review.Cogn Behav Neurol. 2020; 33: 1-15
- Behavioral and cognitive response to selective serotonin reuptake inhibitors in frontotemporal lobar degeneration: a systematic review and meta-analysis.Clin Neuropharmacol. 2021; 44: 175-183
- Improving response inhibition systems in frontotemporal dementia with citalopram.Brain. 2015; 138: 1961-1975
- Classification of neuropsychiatric symptoms requiring antipsychotic treatment in patients with Alzheimer’s disease: analysis of the CATIE-AD study.J Alzheimers Dis. 2016; 50: 839-845
- Behavioral and Psychological symptoms of dementia and antipsychotic drug use in the elderly with dementia in korean long-term care facilities.Drugs Real World Outcomes. 2015; 2: 363-368
- A case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole.Psychogeriatrics. 2017; 17: 509-510
- Aripiprazole for the Treatment of inappropriate sexual behavior: case report of an Alzheimer’s disease patient known as heterosexual with recently shifted sexual orientation to same gender.J Alzheimers Dis Rep. 2018; 2: 117-121
- Prevalence, neurobiology, and treatments for apathy in prodromal dementia.Int Psychogeriatr. 2018; 30: 177-184
- Characterization of apathy in persons with frontotemporal dementia and the impact on family caregivers.Alzheimer Dis Assoc Disord. 2013; 27: 62-67
- Apathy as a treatment target in alzheimer’s disease: implications for clinical trials.Am J Geriatr Psychiatry. 2021; https://doi.org/10.1016/j.jagp.2021.06.016
- The effectiveness of non-pharmacological interventions on apathy in patients with dementia: a systematic review of systematic reviews.Worldviews Evid Based Nurs. 2020; 17: 311-318
- A systematic review of non-pharmacological treatments for apathy in dementia.Int J Geriatr Psychiatry. 2018; 33: e177-e192
- Pharmacological interventions for apathy in Alzheimer’s disease.Cochrane Database Syst Rev. 2018; 5: CD012197
- Effect of methylphenidate on apathy in patients with alzheimer disease: the ADMET 2 randomized clinical trial.JAMA Neurol. 2021; 78: 1324-1332
- A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease.J Clin Psychiatry. 2012; 73: 796-801
- The efficacy of sertraline, escitalopram, and nicergoline in the treatment of depression and apathy in alzheimer’s disease: the okayama depression and apathy project (ODAP).J Alzheimers Dis. 2020; 76: 769-772
- Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer’s disease: A clinical trial.Exp Ther Med. 2019; 17: 1625-1630
- Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study.Medicine (Baltimore). 2020; 99: e21497
- Bupropion for the treatment of apathy in alzheimer disease: a randomized clinical trial.JAMA Netw Open. 2020; 3: e206027
- Bupropion for the treatment of apathy in Huntington’s disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.PLoS One. 2017; 12: e0173872
- Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults.JAMA Netw Open. 2021; 4: e2117573https://doi.org/10.1001/jamanetworkopen.2021.17573
- Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.Brain. 2017; 140: 2104-2111
- The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.Science. 2019; 363: 880-884
- Profound degeneration of wake-promoting neurons in Alzheimer’s disease.Alzheimers Dement. 2019; 15: 1253-1263
- Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.Neurology. 2017; 89: 88-100
- Neuropsychological functioning in older adults with mild cognitive impairment and insomnia randomized to CBT-I or control group.Clin Gerontol. 2018; 41: 136-144
- Effect of a Multimodal Lifestyle Intervention on Sleep and Cognitive Function in Older Adults with Probable Mild Cognitive Impairment and Poor Sleep: A Randomized Clinical Trial.J Alzheimers Dis. 2020; 76: 179-193
- Stages & Behaviors | Alzheimer’s Association.(Available at:) (Accessed January 24, 2022)
- Pharmacotherapies for sleep disturbances in dementia.Cochrane Database Syst Rev. 2020; 11: CD009178
- Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: a randomized trial.Alzheimers Dement. 2020; 16: 541-551
- Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial.Clin Interv Aging. 2014; 9: 947-961
- Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study.Arq Neuropsiquiatr. 2011; 69: 44-49
- Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study.Am J Geriatr Psychiatry. 2014; 22: 1565-1574
- Mirtazapine does not improve sleep disorders in Alzheimer’s disease: results from a double-blind, placebo-controlled pilot study.Psychogeriatrics. 2017; 17: 89-96
- Effectiveness of interventions to directly support food and drink intake in people with dementia: systematic review and meta-analysis.BMC Geriatr. 2016; 16: 26
- Classifying eating-related problems among institutionalized people with dementia.Psychiatry Clin Neurosci. 2016; 70: 175-181
- Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer’s disease.J Neurol Neurosurg Psychiatr. 2002; 73: 371-376
- Predictors of hyperphagia in institutionalized patients with dementia.J Nurs Res. 2014; 22: 250-258
- Factors associated with hyperphagic behavior in patients with dementia living at home.Biol Res Nurs. 2015; 17: 567-573
- Effectiveness of different memory training programs on improving hyperphagic behaviors of residents with dementia: a longitudinal single-blind study.Clin Interv Aging. 2016; 11: 707-720
- Managing abnormal eating behaviours in frontotemporal lobar degeneration patients with topiramate.Psychogeriatrics. 2013; 13: 58-61
- Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors.J Clin Psychiatry. 1997; 58: 212-216
- A review: mealtime difficulties following frontotemporal lobar degeneration.Dement Geriatr Cogn Disord. 2018; 46: 285-297
- Behavioral features in semantic dementia vs other forms of progressive aphasias.Neurology. 2006; 67: 1752-1756
- Managing Care for Frontotemporal Degeneration (FTD) | AFTD.(Available at:) (Accessed January 18, 2022)
- Progression of behavioral disturbances and neuropsychiatric symptoms in patients with genetic frontotemporal dementia.JAMA Netw Open. 2021; 4: e2030194
- Treatment of the behavioral variant of frontotemporal dementia: a narrative review.Dement Neuropsychol. 2021; 15: 331-338
Article info
Publication history
Published online: October 17, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
